# Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).

> PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-16312848-leuprolide:v1`
- Evidence domain: Literature metadata
- Date in source: 2013-11-21
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-16312848-leuprolide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-16312848-leuprolide-v1.json
- Content SHA-256: `a0672b4de80aec902e9b26b7ddd57fe28455b01f605a5fbb996ebbb7199b7030`

## Claims and source pins

### Headline

Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide). ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

### Summary

PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

### Paragraph 1

PubMed lists PMID 16312848 in Journal of chemotherapy (Florence, Italy) as Journal Article, with publication-date metadata of 1989-07 (month precision). PeptideScanner associated the retained record with the identity slug leuprolide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`](#source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383))

## Sources

<a id="source-pubmed-observation-pmid-16312848-2013-11-21-2290e5574383"></a>
- **Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide). · retained source version 1:2013-11-21:current:2290e5574383619557754336864f60d972e0c36c633119bf5829a895bf4edf71** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/16312848/) (`pubmed-observation-pmid-16312848-2013-11-21-2290e5574383`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide)." Version 1, published 2026-08-16. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-16312848-leuprolide-v1.json SHA-256: a0672b4de80aec902e9b26b7ddd57fe28455b01f605a5fbb996ebbb7199b7030.